长江润发健康产业股份有限公司 关于购买董事、监事及高级管理人员责任保险的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、 误导性陈述或者重大遗漏。 长江润发健康产业股份有限公司（以下简称"公司"）于2023年8月26日召开 的第五届董事会第十一次会议、第五届监事会第十一次会议，分别审议通过了《关 于购买董事、监事及高级管理人员责任保险的议案》，为进一步完善公司风控体 系，促进公司董事、监事及高级管理人员合理行使权利，积极履行职责，根据中 国证监会《上市公司治理准则》等规则，公司拟为董事、监事及高管人员购买责 任保险（以下简称"董监高责任险"），本议案将提交公司股东大会审议，现将具体 情况公告如下： 证券代码：002435 证券简称：长江润发 公告编号：2023-051 一、董监高责任险的具体方案 1、投保人：长江润发健康产业股份有限公司。 2、被保险人：公司及全体董事、监事、高级管理人员（具体以公司与保险 公司协商确定的范围为准）。 3、责任限额：不超过人民币 10,000 万元/年（具体以公司与保险公司协商 确定的数额为准）。 二、独立董事意见 公司独立董事认为：公司为董事、监事及高级管 ...

索 引 号 bm56000001/2023-00009618 分 类 发布机构 发文日期 1692557640000 名 称 江苏证监局关于对陈柏霖采取出具警示函措施的决定 文 号 〔2023〕129号 主 题 词 江苏证监局关于对陈柏霖采取出具警示函措施的决定 陈柏霖: 你的上述行为违反了《上市公司股东、董监高减持股份的若干规定》(证监会公告〔2017〕9号)第十一 条第一款及《深圳证券交易所上市公司股东及董事、监事、高级管理人员减持股份实施细则》(深证上 〔2017〕820号)第五条第二款规定。根据《上市公司股东、董监高减持股份的若干规定》(证监会公告 〔2017〕9号)第十四条的规定,我局决定对你采取出具警示函的监管措施,并记入证券期货市场诚信档案。你 应充分吸取教训,加强对证券法律法规的学习,严格规范减持上市公司股份的行为,杜绝此类事件再次发生。你 应在收到本决定书的10个工作日内向我局提交书面报告。 如果对本监督管理措施不服,可以在收到本决定书之日起60日内向中国证券监督管理委员会提出行政复 议申请,也可以在收到本决定书之日起6个月内向有管辖权的人民法院提起诉讼。复议与诉讼期间,上述行政监 管措施不 ...

本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误导 性陈述或者重大遗漏。 长江润发健康产业股份有限公司（以下简称"公司"）于近日接到公司控股 股东长江润发集团有限公司（以下简称"长江润发集团"）的通知，获悉长江润 发集团将其所持有本公司的部分股份办理了质押手续，具体情况如下： 二、股东股份累计质押/冻结情况 证券代码：002435 证券简称：长江健康 公告编号：2023-046 长江润发健康产业股份有限公司 关于控股股东部分股份质押的公告 股东 名称 是否为控股 股东及其一 致行动人 本次质 押数量 （万股） 占其所 持股份 比例 占公司 总股本 比例 是否 为限 售股 是否 补充 质押 质押 起始日 质押 到期日 质权人 质押 用途 长江润发 集团 是 1,500 4.48% 1.21% 否 否 2023年 8 月 16 日 办理解除 质押手续 之日止 兴业银行股份 有限公司苏州 分行 补充 流动 资金 一、股东股份质押的基本情况 截至本公告披露日，控股股东及其一致行动人所持质押股份情况如下： 股东 名称 持股数量 （万股） 持股 比例 累计质押 数量 （万股） 占其所持 股份比例 占总股 ...

证券代码：002435 证券简称：长江健康 长江润发健康产业股份有限公司 2022 年度业绩说明会投资者关系活动记录表 编号：20230510 投资者关系活动 类别 □特定对象调研 □分析师会议 □媒体采访 √业绩说明会 □新闻发布会 □路演活动 □现场参观 □电话会议 □其他： （请文字说明其他活动内容） 参与单位名称 及人员姓名 长江健康2022年度业绩说明会采用网络远程方式进行，面向全体投资 者。 时间 2023 年 5 月 10 日 15:00-17:00 地点 公司通过"中国证券网路演中心"（http://roadshow.cnstock.com/）采用网络 远程的方式召开业绩说明会 公司接待人员 姓名 董事长：郁霞秋 总裁：陆一峰 财务总监：张义 董事会秘书：孙文遥 独立董事：舒知堂 投资者关系活动 主要内容介绍 1.公司 2022 年度营收是下滑的，为什么净利润反向大幅增长？ 答：您好，2022 年公司累计实现营业收入 346,955.78 万元，同比下降 20.60%；实现归属于上市公司股东的净利润 6,519.04 万元，较上年同 期增长 115.79%。主要是 2021 年度公司计提商誉减 ...

Financial Performance - The company's operating revenue for Q1 2023 was CNY 873,535,602.23, a decrease of 3.52% compared to CNY 905,405,104.96 in the same period last year[5] - Net profit attributable to shareholders was CNY 60,141,015.34, down 3.18% from CNY 62,117,583.39 year-on-year[5] - The net profit excluding non-recurring gains and losses increased by 36.44% to CNY 53,752,528.72 from CNY 39,396,380.55 in the previous year[5] - Total revenue for Q1 2023 was CNY 873,535,602.23, a decrease of 3.7% compared to CNY 905,405,104.96 in Q1 2022[19] - Net profit for Q1 2023 was CNY 59,052,807.21, an increase of 3.5% from CNY 57,058,225.75 in Q1 2022[20] - The total comprehensive income attributable to the parent company was ¥59,653,332.37, down from ¥61,951,832.05, reflecting a decline of 3.71%[21] Cash Flow and Liquidity - The net cash flow from operating activities was CNY 4,688,490.14, a significant decline of 97.41% compared to CNY 181,228,927.13 in the same period last year[5] - Operating cash flow for Q1 2023 was ¥4,688,490.14, significantly lower than ¥181,228,927.13 in the same period last year, indicating a decrease of 97.42%[23] - Cash and cash equivalents at the end of Q1 2023 were CNY 2,491,636,136.31, up from CNY 1,680,084,001.51 at the beginning of the year[16] - Cash and cash equivalents at the end of Q1 2023 increased to ¥2,401,904,913.35 from ¥1,714,061,391.05, representing a rise of 40.06%[24] - Cash inflow from operating activities totaled ¥988,161,809.86, down 42.09% from ¥1,708,388,783.31 in Q1 2022[23] - Cash outflow from operating activities was ¥983,473,319.72, a decrease of 35.69% compared to ¥1,527,159,856.18 in the previous year[23] - Investment activities generated a net cash inflow of ¥363,389,856.94, contrasting with a net outflow of ¥271,172,451.88 in Q1 2022[23] - Financing activities produced a net cash inflow of ¥444,881,419.92, compared to ¥114,403,672.52 in the same quarter last year, marking an increase of 288.06%[23] Assets and Liabilities - Total assets at the end of the reporting period reached CNY 7,764,956,292.55, reflecting a growth of 5.33% from CNY 7,371,749,936.56 at the end of the previous year[5] - Total assets as of the end of Q1 2023 were CNY 7,764,956,292.55, compared to CNY 7,371,749,936.56 at the beginning of the year[17] - Total liabilities increased to CNY 3,129,755,867.45 from CNY 2,721,908,162.82, an increase of 15.0%[17] Shareholder Information - The total number of common shareholders at the end of the reporting period is 50.124 million[12] - The largest shareholder, Changjiang Runfa Group, holds 38.08% of shares, amounting to 470,667,365 shares, with 289,334,000 shares pledged[12] - The second-largest shareholder, Zhongshan Songde Zhangjiagang Free Trade Zone Pharmaceutical Industry Equity Investment Enterprise, holds 9.84% of shares, totaling 121,607,997 shares, with 72,033,898 shares frozen[12] - The top ten shareholders include several entities with significant holdings, such as Dongwu Venture Capital with 7.67% (94,830,788 shares) and Huazhong Asset Management with 2.14% (26,448,671 shares)[12] - The company has not disclosed any participation in margin trading by the top ten shareholders[13] - The total number of preferred shareholders is zero, indicating no preferred shares outstanding[14] Government Support and Initiatives - The company received government subsidies totaling CNY 5,753,740.57, mainly from fiscal support and rewards[6] - The company is focusing on market expansion through participation in national drug procurement initiatives[14] - The company’s subsidiary, Hainan Hailing Chemical Pharmaceutical Co., participated in the eighth batch of national centralized drug procurement and is expected to be selected for two products[14] - The company reported that it has passed the consistency evaluation for two injectable drugs, which are expected to be included in the centralized procurement[14] Expenses - Total operating costs for Q1 2023 were CNY 792,274,243.76, down 7.0% from CNY 852,360,005.87 in the previous year[20] - The company reported a decrease in sales expenses to CNY 183,732,085.40 from CNY 204,111,580.72, a reduction of 10.0%[20] - Research and development expenses for Q1 2023 were CNY 10,056,677.28, down from CNY 11,527,938.07, a decrease of 12.8%[20] Return on Equity - The weighted average return on equity was 1.33%, slightly down from 1.37% in the previous year[5] - The basic and diluted earnings per share for Q1 2023 were both ¥0.0487, slightly down from ¥0.0503 in Q1 2022[21]

Financial Performance - The company's operating revenue for 2022 was ¥3,469,557,831.87, a decrease of 20.60% compared to ¥4,369,815,125.02 in 2021[6]. - The net profit attributable to shareholders for 2022 was ¥65,190,392.13, representing a significant increase of 115.79% from a loss of ¥412,986,660.97 in 2021[6]. - The net profit attributable to shareholders after deducting non-recurring gains and losses was ¥22,660,068.45, up 103.79% from a loss of ¥597,984,717.38 in 2021[6]. - The net cash flow from operating activities increased by 77.72% to ¥523,058,080.76 from ¥294,312,912.85 in 2021[6]. - The total assets at the end of 2022 were ¥7,371,749,936.56, an increase of 2.82% from ¥7,169,632,208.56 at the end of 2021[6]. - The basic earnings per share for 2022 was ¥0.0527, a recovery from a loss of ¥0.3341 in 2021, marking an increase of 115.77%[6]. - The company reported a weighted average return on equity of 1.44% for 2022, a significant improvement from -8.72% in 2021[6]. - The company received government subsidies amounting to ¥23,622,681.24 in 2022, down from ¥37,461,590.11 in 2021[6]. - The company achieved total operating revenue of CNY 3,469,557,831.8, a year-on-year decrease of 20.60%[45]. - The net profit attributable to shareholders was CNY 65,190,400, an increase of 115.79% compared to the previous year[45]. Business Operations - The company has not made significant changes to its main business, which focuses on pharmaceutical product research, production, and sales, as well as specialized medical services in obstetrics and gynecology[22]. - The company completed the acquisition of 100% equity in Changjiang Runfa Zhangjiagang Free Trade Zone Pharmaceutical Investment Co., Ltd. in 2016, adding pharmaceutical assets to its portfolio[21]. - The company operates in the pharmaceutical industry, focusing on research, production, and sales, with significant contributions from its subsidiaries, including Hailing Pharmaceutical and Huaxin Pharmaceutical[38]. - Hailing Pharmaceutical has over 130 product specifications and ranks second in the domestic public hospital market for systemic antibacterial drugs, with core products like "Injectable Cefotaxime" and "Injectable Cefoperazone" ranking fourth and fifth respectively[39]. - The company has achieved consistency evaluation for 12 products and 23 specifications in the past three years, with 5 products and 9 specifications successfully winning bids in centralized procurement[39]. - The company is expanding its women's and children's healthcare services in response to the increasing demand driven by the "three-child" policy and rising rates of gynecological diseases among women[36]. - The company has expanded its hospital coverage to over 3,000 hospitals, achieving a hospital coverage rate of 39.83%[45]. - The company is committed to innovation, with ongoing research and development efforts to enhance its product line and improve quality control systems[41]. Market and Sales - The pharmaceutical segment generated revenue of CNY 1,649,420,555.3, accounting for 47.54% of total revenue, with a year-on-year decline of 27.29%[48]. - The elevator guide rail segment reported revenue of CNY 1,820,137,276.5, representing 52.46% of total revenue, down 13.38% year-on-year[48]. - The company achieved a 101.62% increase in the equity acquisition project of Shandong Huaxin, with a total investment of RMB 28,477 million[77]. - The company plans to enhance its product pipeline through the approval of generic drugs and improved formulations, aiming for a significant market impact[60]. - The company is exploring strategic acquisitions to enhance its product portfolio, with a target of completing at least one acquisition by the end of 2023[112]. Research and Development - The company is investing 200 million RMB in R&D for new technologies in the healthcare sector over the next two years[112]. - Research and development expenses increased by 25% in 2022, totaling 5,500 million, to support innovation[191]. - The company plans to obtain production approval for 5 new products and initiate 24 new projects in 2023, with a focus on accelerating 33 ongoing products[87]. - The company is conducting clinical trials for new functions of its proprietary product, with exclusivity protection extending until 2030[60]. Environmental Compliance - The company strictly adheres to environmental protection laws and regulations, with no penalties incurred for violations during the reporting period[144]. - The company has implemented new technologies in wastewater treatment, enhancing overall efficiency and compliance[147]. - The company is focused on maintaining compliance with water pollution discharge standards across its facilities[149]. - The company emphasizes energy structure optimization and clean production, aligning with national goals of carbon peak and carbon neutrality[154]. Corporate Governance - The company’s financial report is guaranteed to be true, accurate, and complete by its board of directors and management[3]. - The company has established an independent financial department with a complete accounting system, allowing for independent financial decision-making and self-accounting[101]. - The company maintains clear ownership of assets, with no instances of funds or resources being occupied or used by the controlling shareholder[101]. - The company has a complete production and administrative organization that operates independently from the controlling shareholder, with no interference from any external parties[101]. Employee and Management - The total number of employees at the end of the reporting period was 2,405, with 2,384 from major subsidiaries[130]. - The company has a competitive salary system based on internal and external labor market conditions, with a clear structure including basic salary, performance pay, and various allowances[131]. - The company’s training plan includes various categories such as pre-job training, industry knowledge, and management training to enhance employee skills[132]. - The total remuneration for directors, supervisors, and senior management during the reporting period amounted to 653.37 million CNY[119]. Future Outlook - The company has set a revenue guidance of 1.5 billion RMB for the fiscal year 2023, projecting a growth of 25% compared to 2022[112]. - The company plans to use retained earnings primarily for operational funding, external investments, acquisitions, and major capital expenditures to promote business growth[135]. - The company aims to reduce operational costs by 15% through efficiency improvements and automation initiatives[112]. - The company has set a performance guidance for 2023, targeting a revenue growth of 30%[191].

证券代码：002435 证券简称：长江健康 公告编号：2023-024 长江润发健康产业股份有限公司 关于举办 2022 年度网上业绩说明会的公告 本公司及全体董事保证公告内容真实、准确和完整，不存在虚假记载、误 导性陈述或者重大遗漏。 长江润发健康产业股份有限公司（以下简称"公司"）《2022年年度报告全 文及其摘要》已于2023年4月20日在巨潮资讯网(http://www.cninfo.com.cn)披露。 为了便于广大投资者更深入、全面地了解公司情况，公司定于2023年5月10日（星 期三）15:00-17:00采用网络远程的方式举办2022年度网上业绩说明会，投资者可 登录"中国证券网路演中心"（http://roadshow.cnstock.com/）参与本次年度业绩 说明会。 公司出席本次网上业绩说明会人员有：董事长郁霞秋女士，总裁陆一峰先生， 财务总监张义先生，董事会秘书孙文遥先生，独立董事舒知堂先生。欢迎广大投 资者积极参与。 欢迎广大投资者积极参与！ 特此公告。 长江润发健康产业股份有限公司 董事会 2023年4月20日 ...

证券代码：002435 证券简称：长江健康 编号：20220510 长江润发健康产业股份有限公司 2021 年度业绩说明会投资者关系活动记录表 | --- | --- | --- | |-------------------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | | □媒体采访 √业绩说明会 | | | 投资者关系 | □新闻发布会 □路演活动 | | | 活动类别 | □现场参观 | | | | □其他（请文字说明其他活动内容） | | | 参与单位名称及 人员姓名 | 长江健康 2021 向全体投 ...

Financial Performance - The company's revenue for Q3 2022 was ¥951,832,790.96, representing a decrease of 19.04% compared to the same period last year[5] - Net profit attributable to shareholders was ¥16,375,135.40, down 90.10% year-on-year, while the net profit excluding non-recurring gains and losses was ¥10,653,063.48, a decrease of 61.34%[5] - The company's basic earnings per share for Q3 2022 was ¥0.0132, a decline of 90.14% compared to the same period last year[5] - Total operating revenue for the third quarter was ¥2,750,789,217.12, a decrease of 18.5% compared to ¥3,374,049,354.76 in the same period last year[19] - Net profit for the quarter was ¥97,283,921.32, a decline of 69.2% from ¥316,044,702.20 in the previous year[20] - Basic earnings per share decreased to ¥0.0868, down from ¥0.2570 in the same quarter last year[21] - The company reported a comprehensive income total of ¥99,645,489.82, down from ¥315,799,330.37 in the previous year[21] Cash Flow - The operating cash flow for the year-to-date period reached ¥346,455,455.66, showing a significant increase of 242.99%[10] - The net cash flow from operating activities for Q3 2022 was ¥346,455,455.66, a significant improvement compared to a negative cash flow of ¥242,301,623.97 in Q3 2021[24] - Total cash outflow from operating activities amounted to ¥2,931,988,495.68, down from ¥4,954,643,622.21 in the same period last year[24] - Cash inflow from financing activities reached ¥1,300,861,466.91, compared to ¥955,574,111.69 in Q3 2021, indicating a 36% increase[24] - The net cash flow from financing activities was ¥227,979,992.01, a substantial increase from ¥17,265,006.59 in the previous year[24] - The total cash and cash equivalents at the end of Q3 2022 stood at ¥2,062,533,053.46, up from ¥1,286,352,038.29 at the end of Q3 2021[24] Assets and Liabilities - Total assets at the end of the reporting period were ¥7,297,784,554.71, reflecting a 1.79% increase from the end of the previous year[5] - Current assets total 4,098,893,620.87 RMB, compared to 3,997,328,585.49 RMB at the start of the year[16] - The company reported a total current liability of 2,014,936,448.19 RMB, compared to 1,918,649,965.75 RMB previously[16] - The total liabilities amounted to ¥2,591,617,698.51, slightly up from ¥2,562,945,067.79 in the previous year[20] - The total equity attributable to shareholders of the parent company increased to ¥4,608,622,015.72 from ¥4,498,932,071.60 year-on-year[20] Investments and Expenses - The company reported a 31.48% increase in trading financial assets, totaling ¥365,822,520.56, primarily due to an increase in short-term investments[10] - The company experienced a significant reduction in sales expenses, which amounted to ¥533,487,909.49, down 52.11% year-on-year[10] - Research and development expenses were ¥30,609,395.13, down 26.2% from ¥41,484,518.46 year-on-year[20] - Sales expenses significantly decreased to ¥533,487,909.49, down 52.2% from ¥1,113,955,831.75 in the previous year[19] Shareholder Information - Total number of common shareholders at the end of the reporting period is 60,102[12] - The largest shareholder, Changjiang Runfa Group, holds 38.08% of shares, totaling 470,667,365 shares, with 319,334,000 shares pledged[12] Other Financial Metrics - The company recorded a 1069.43% increase in credit impairment losses, totaling ¥33,161,844.09, primarily due to the consolidation of Hunan Sanqing[10] - The company received government subsidies amounting to ¥21,895,267.70, which is a 356.26% increase compared to the previous year[10] - Cash paid to employees and for employee benefits was ¥210,170,277.86, compared to ¥200,664,975.59 in the same quarter last year[24] - The impact of exchange rate changes on cash and cash equivalents was positive at ¥2,953,443.48, compared to a negative impact of ¥2,760,242.77 in the previous year[24]

Financial Performance - The company's operating revenue for the first half of 2022 was approximately ¥1.80 billion, a decrease of 18.17% compared to ¥2.20 billion in the same period last year[21]. - The net profit attributable to shareholders was approximately ¥90.95 million, down 40.20% from ¥152.10 million in the previous year[21]. - The net profit after deducting non-recurring gains and losses was approximately ¥66.76 million, a decline of 50.26% compared to ¥134.21 million in the same period last year[21]. - The company's total revenue for the reporting period was ¥1,798,956,426.16, representing an 18.17% decrease compared to ¥2,198,362,472.13 in the same period last year[39]. - The revenue from the pharmaceutical segment was ¥742,887,178.88, accounting for 41.30% of total revenue, which is a 35.62% decline from ¥1,153,852,763.71 in the previous year[41]. - The elevator guide rail segment generated ¥963,918,664.09, making up 53.58% of total revenue, with a slight increase of 2.13% compared to ¥943,843,204.67 last year[41]. - The medical services segment revenue was ¥92,150,583.19, which is an 8.46% decrease from ¥100,666,503.75 in the previous year[41]. - The company's total comprehensive income for the first half of 2022 was CNY 5,839,881.26, significantly higher than CNY 923,443.37 in the first half of 2021, marking an increase of approximately 532%[151]. Cash Flow and Assets - The net cash flow from operating activities improved significantly to approximately ¥217.73 million, compared to a negative cash flow of ¥123.16 million in the previous year, representing a 276.79% increase[21]. - The company reported a significant increase in cash and cash equivalents, which rose by 58.40% to ¥357,284,868.92 from ¥225,555,673.31 last year[39]. - Cash flow from operating activities generated a net amount of CNY 217,728,323.07, a turnaround from a negative cash flow of CNY -123,159,871.23 in the first half of 2021[152]. - The total cash and cash equivalents at the end of the first half of 2022 amounted to CNY 2,124,603,949.08, up from CNY 1,732,431,510.36, representing a growth of approximately 22.6%[138]. - The company's total assets at the end of the reporting period were approximately ¥7.36 billion, an increase of 2.59% from ¥7.17 billion at the end of the previous year[21]. - Cash and cash equivalents increased to 2,124,603.94 yuan, accounting for 28.89% of total assets, up from 24.16% last year[48]. Shareholder Information - The company plans not to distribute cash dividends or issue bonus shares for this period[5]. - The total number of shares before the change was 36,388,472, with a proportion of 72.00%, and after the change, it decreased to 33,430,073, representing a proportion of 73.00%[118]. - The largest shareholder, Changjiang Runfa Group, holds 38.08% of the shares, totaling 470,667,365 shares[124]. - The company reported a profit distribution of 9.151 million yuan to shareholders during the period[169]. - The total number of common shareholders at the end of the reporting period is 66,156[123]. Research and Development - Research and development expenses decreased by 25.01% to ¥22,604,807.83 from ¥30,142,355.28 year-on-year[39]. - The company has allocated 90 million RMB for research and development in new technologies and products[162]. - The company is actively pursuing new product development and technological advancements to enhance its product offerings and maintain competitive advantages[35]. Market Position and Strategy - The company operates primarily in the pharmaceutical industry, focusing on research, production, and sales of medical products, with significant segments in gynecology and mechanical products[29]. - The company is positioned to benefit from the increasing demand for maternal and child healthcare services due to the "three-child" policy and rising incidence of gynecological diseases[32]. - The company plans to expand its market presence and invest in new product development to drive future growth[163]. - The company aims to enhance operational efficiency through strategic mergers and acquisitions in the upcoming quarters[163]. Environmental and Social Responsibility - The company has implemented measures to reduce carbon emissions, including transitioning from oil to gas and coal to gas, enhancing energy efficiency[82]. - The company has maintained compliance with environmental regulations, with no instances of exceeding emission standards reported during the reporting period[81]. - The company actively engages in social responsibility initiatives, including donations of pandemic prevention materials and participation in health-related public welfare projects[85]. Risk Management - The company faces risks related to industry policy changes, production cost increases, and environmental regulations, which may impact operations and profitability[68]. - The company emphasizes quality control and compliance with national regulations to mitigate risks associated with drug quality and safety[69]. - The company plans to enhance internal controls and risk management to ensure sustainable development and operational safety[71]. Financial Reporting and Compliance - The semi-annual financial report was not audited[91]. - The financial report was approved by the board of directors on August 28, 2022[170]. - The company prepares its financial statements based on the going concern principle, adhering to the relevant accounting standards and regulations[172].